New crown vaccine experts who have not completed the test in China warned

Source: Reuters

China will vaccinate tens of thousands of people in the experimental vaccine, which has attracted attention internationally.Because the vaccine has not yet completed the standard test procedure, some experts have expressed concern about their safety.

China launched the emergency use plan for vaccine in July, and the vaccines were vaccinated by some people under the Sinopharm Group and the three experiments developed by the Sinopharm Group and the Kochi Biotechnology Co., Ltd. listed in the United States.Earlier, another vaccine developed by Kangshino Bio shares 6185.HK had been approved in June to use in the Chinese army.

This is aimed at protecting backbone personnel and reducing the risk of recurrence of the epidemic.In the case of governments around the world for vaccine supply, China's vaccine has attracted attention, which may help change the impression that the outside world has previously played the role of China in this epidemic.

Beijing has not announced the official data of vaccination of domestic target groups. These groups include medical, transportation, and food market staff.

However, Sinopharm Group and Kexing Bio have confirmed that at least tens of thousands of people have vaccinated vaccines.In addition, the National Medicine Group claims that there have been hundreds of thousands of doses. Among the vaccines developed by the company, there is one inoculation twice or three times.

China endorses the test vaccine in an open and bottom way and establishes social support.The vaccination in advance includes the executives of the Koxing Biological and Sinopharm Group, and the military research director.

Wu Guizhen, Chief Expert of Biological Safety of the China Centers for Disease Control and Prevention, said this week that she had injected vaccines in April.She announced that at least some vaccines could be provided to the public in November.

In an interview with TV stations, Wu Guizhen said that no one who vaccinated the vaccine has infected the new crown virus so far. So far (vaccination) has progressed smoothly without side effects.

Wu Guizhen's statement was roughly consistent with the comments of the Chinese Medicine Group last week. None of the tens of thousands of vaccines went to high -risk countries and regions infected, and there were no cases where there were obvious adverse reactions.

Safety concerns

China's approach is different from many Western countries. Experts from these countries warn that they should not authorize vaccines that have not been completed in urgent use of the test, because they lack the understanding of long -term effects and potential side effects.

Anna Durbin, a vaccine researcher at Johns Hopkins University, said that China's emergency vaccine plans are very problematic. It is impossible to judge the effect of vaccine without clinical trial standard control group.

Give people vaccine, but do not know if they can protect them. Durbin said to Reuters and said that the recipients of the experimental vaccine may give up other protection measures.

Foreign buyers

The UAE authorized an emergency use of a type of vaccine from the National Medicine Group this week. In the world, the first emergency approval of the use of Chinese vaccines was only six weeks before the UAE began to start human test.UAE officials reported that in these trials, there were slight side effects expected, but there were no serious side effects.

Sources familiar with the negotiations told Reuters that several countries have contacted Kangxino Bio and said that the approval of the military can help attract foreign buyers' interest.The person refused to disclose the name of the country participating in the negotiations.

Kangxino Bio did not reply to the request.Kangxino Bio has plans to test the company's vaccine developed in cooperation with Chinese military research units in Pakistan and Russia.

Zhang Yuntao, vice president of China Biotechnology Co., Ltd., told Reuters that his company has received the intention of purchasing about 500 million test vaccines from some overseas countries.

Philippine President Rodrigo Duterte said on Monday that the Philippines will prioritize the purchase of new crown vaccines in China and Russia, saying that the Philippine government has conducted consultations with China and Russia.He also specifically mentioned the differences between China and other countries, saying that China does not require deposit or prepaid.

He said: What is attractive in China is that you don't need to begging or begging them.The problem in Western countries is that they only care about money.